BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18425381)

  • 1. Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells.
    Lazarevic B; Karlsen SJ; Saatcioglu F
    Oncol Rep; 2008 May; 19(5):1231-5. PubMed ID: 18425381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways.
    Takahashi Y; Hursting SD; Perkins SN; Wang TC; Wang TT
    Mol Carcinog; 2006 Jan; 45(1):18-25. PubMed ID: 16299812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
    Arnoldussen YJ; Lorenzo PI; Pretorius ME; Waehre H; Risberg B; Maelandsmo GM; Danielsen HE; Saatcioglu F
    Cancer Res; 2008 Nov; 68(22):9255-64. PubMed ID: 19010898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
    Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells.
    Davis JN; Kucuk O; Sarkar FH
    Mol Carcinog; 2002 Jun; 34(2):91-101. PubMed ID: 12112315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
    Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
    Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
    Singh SV; Choi S; Zeng Y; Hahm ER; Xiao D
    Cancer Res; 2007 Aug; 67(15):7439-49. PubMed ID: 17671214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
    Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
    Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens regulate protein kinase Cdelta transcription and modulate its apoptotic function in prostate cancer cells.
    Gavrielides MV; Gonzalez-Guerrico AM; Riobo NA; Kazanietz MG
    Cancer Res; 2006 Dec; 66(24):11792-801. PubMed ID: 17178875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase.
    Shao C; Wang Y; Yue HH; Zhang YT; Shi CH; Liu F; Bao TY; Yang ZY; Yuan JL; Shao GX
    J Androl; 2007; 28(6):804-12. PubMed ID: 17581945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of NKX3.1 in LNCaP prostate cancer cells by RNA interference.
    Possner M; Heuser M; Kaulfuss S; Scharf JG; Schulz W; Hermann-Ringert R; Thelen P
    Int J Oncol; 2008 Apr; 32(4):877-84. PubMed ID: 18360715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: a comparison study using DNA microarray.
    Takahashi Y; Lavigne JA; Hursting SD; Chandramouli GV; Perkins SN; Kim YS; Wang TT
    Mol Carcinog; 2006 Dec; 45(12):943-56. PubMed ID: 16865672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
    Mukherjee B; Mayer D
    Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.